These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 22790386)

  • 1. Cell population in spleens during antibody-mediated rejection: pathologic and clinical findings.
    Tzvetanov I; Spaggiari M; Oberholzer J; Setty S; Stephenson A; Thielke J; West-Thielke P; Jeon H; Danielson KK; Kaplan B; Benedetti E
    Transplantation; 2012 Aug; 94(3):255-62. PubMed ID: 22790386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of splenectomy in the setting of refractory humoral rejection after kidney transplantation.
    Tzvetanov I; Spaggiari M; Jeon H; Roca RG; Bhati C; Oberholzer J; Benedetti E
    Transplant Proc; 2012 Jun; 44(5):1254-8. PubMed ID: 22663995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation.
    Orandi BJ; Zachary AA; Dagher NN; Bagnasco SM; Garonzik-Wang JM; Van Arendonk KJ; Gupta N; Lonze BE; Alachkar N; Kraus ES; Desai NM; Locke JE; Racusen LC; Segev DL; Montgomery RA
    Transplantation; 2014 Oct; 98(8):857-63. PubMed ID: 25121475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful rescue of refractory, severe antibody mediated rejection with splenectomy.
    Kaplan B; Gangemi A; Thielke J; Oberholzer J; Sankary H; Benedetti E
    Transplantation; 2007 Jan; 83(1):99-100. PubMed ID: 17220802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment.
    Nordén G; Briggs D; Cockwell P; Lipkin G; Mjörnstedt L; Mölne J; Ready A; Rydberg L; Samuelsson O; Svalander CT; Breimer ME
    Xenotransplantation; 2006 Mar; 13(2):148-53. PubMed ID: 16623810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients.
    Matignon M; Tagnaouti M; Audard V; Dahan K; Lang P; Grimbert P
    Transplant Proc; 2007 Oct; 39(8):2565-7. PubMed ID: 17954175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloantibodies and the outcome of cadaver kidney allografts.
    Vasilescu ER; Ho EK; Colovai AI; Vlad G; Foca-Rodi A; Markowitz GS; D'Agati V; Hardy MA; Ratner LE; Suciu-Foca N
    Hum Immunol; 2006 Aug; 67(8):597-604. PubMed ID: 16916655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splenectomy does not offer immunological benefits in ABO-incompatible liver transplantation with a preoperative rituximab.
    Raut V; Mori A; Kaido T; Ogura Y; Taku I; Nagai K; Sasaki N; Endo K; Hata T; Yagi S; Egawa H; Uemoto S
    Transplantation; 2012 Jan; 93(1):99-105. PubMed ID: 22094955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience.
    Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J
    Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens.
    Tanabe K; Ishida H; Shimizu T; Omoto K; Shirakawa H; Tokumoto T
    Contrib Nephrol; 2009; 162():61-74. PubMed ID: 19001814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival.
    Vlad G; Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N
    Hum Immunol; 2009 Aug; 70(8):589-94. PubMed ID: 19375470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The strength of donor-specific antibody is a more reliable predictor of antibody-mediated rejection than flow cytometry crossmatch analysis in desensitized kidney recipients.
    Mujtaba MA; Goggins W; Lobashevsky A; Sharfuddin AA; Yaqub MS; Mishler DP; Brahmi Z; Higgins N; Milgrom MM; Diez A; Taber T
    Clin Transplant; 2011; 25(1):E96-102. PubMed ID: 20977497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
    Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
    Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
    Hardinger KL; Murillo D
    Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantation.
    Kayler LK; Farber JL; Colombe B; LaCava D; Friedewald JJ; Ratner LE
    Transpl Int; 2006 Feb; 19(2):128-39. PubMed ID: 16441362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
    Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
    Yuan XP; Wang CX; Gao W; Fu Q; He XS
    Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab induction therapy in highly sensitized kidney transplant recipients.
    Yin H; Wan H; Hu XP; Li XB; Wang W; Liu H; Ren L; Zhang XD
    Chin Med J (Engl); 2011 Jul; 124(13):1928-32. PubMed ID: 22088448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation.
    Egawa H; Ohmori K; Haga H; Tsuji H; Yurugi K; Miyagawa-Hayashino A; Oike F; Fukuda A; Yoshizawa J; Takada Y; Tanaka K; Maekawa T; Ozawa K; Uemoto S
    Liver Transpl; 2007 Apr; 13(4):579-88. PubMed ID: 17394164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.